Form 4: Zimmer Biomet Exec. VP, CFO Suketu Upadhyay Reports Acquisition of Restricted Stock Units

Suketu Upadhyay, Exec. VP and CFO of Zimmer Biomet Holdings, Inc., reports the acquisition of 19,090 restricted stock units on February 25, 2025, according to a Form 4 filing with the SEC.

Summary

• On February 25, 2025, Suketu Upadhyay, the Executive Vice President and CFO of Zimmer Biomet Holdings, Inc., acquired 19,090 restricted stock units.
• These restricted stock units represent a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock each.
• The restricted stock units vest annually over three years, starting on February 25, 2026, in increments of one-third each year.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, which is generally viewed as a positive alignment of interests.

Positives

• The acquisition of restricted stock units by a key executive can be seen as a positive sign, aligning their interests with the company's long-term performance.

Future Outlook

The restricted stock units vest over a three-year period, indicating a long-term incentive for the executive.

Industry Context

Executive compensation packages often include restricted stock units to incentivize performance and align executive interests with shareholder value. This is a common practice in publicly traded companies.

Comparison to Industry Standards

• Executive compensation packages, including restricted stock units, are common across the medical device industry.
• Companies like Medtronic, Stryker, and Johnson & Johnson also utilize similar equity-based compensation to incentivize their executives.

Stakeholder Impact

• Shareholders may view the granting of restricted stock units as a positive incentive for the executive to drive long-term value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates